The DOI matches its Crossref record.
Effects of Insulin on Vascular Tone and Sympathetic Nervous System in NIDDM
Open accessAbstract
Chronic activation of the sympathetic nervous system may be a pathogenetic mechanism by which hyperinsulinemia induces cardiovascular damage in insulin-resistant NIDDM patients. The influence of physiological hyperinsulinemia (∼ 700 pmol/l) on basal and stimulated sympathetic outflow was studied in 12 lean normotensive subjects with well-controlled NIDDM without complications and in 13 matched control subjects. Forearm blood flow (FBF) was measured with forearm plethysmography; sympathetic nervous system activity was assessed by the [3H]norepinephrine (NE) tracer method. NIDDM patients were insulin resistant (glucose infusion rates 31.8 ± 3.8 vs. 48.7 ± 2.0 mumol·kg−1 · min−1 in control subjects, P < 0.01). After a mixed meal, NIDDM patients showed a hyperinsulinemic response (2-h insulin levels: NIDDM patients 324 ± 34 pmol/l, control subjects 165 ± 19 pmol/l, P < 0.001). Insulin infusion induced a vasodilator response (not significantly different between the groups). Arterial plasma NE levels and total-body NE spillover increased significantly (total spillover in NIDDM patients from 0.77 ± 0.09 to 1.18 ± 0.16 nmol · m−2 · min−1, in control subjects from 0.98 ± 0.14 to 1.23 ± 0.18 nmol · m−2 · min−1 P < 0.01 for all, not different between groups). Total-body NE clearance did not change. Sympathetic stimulation (lower-body negative pressure [LBNP] 15 mmHg) induced forearm vasoconstriction and increased arterial and venous plasma NE and total NE spillover. Responses of FBF and NE kinetics to LBNP were not significantly different between groups and were not altered by hyperinsulinemia. Although these nonobese subjects with uncomplicated NIDDM showed postprandial hyperinsulinemia and resistance to the effect of insulin on glucose metabolism, this group was not resistant to the vasodilator and sympathetic stimulant effects of insulin. Responses to sympathetic stimuli (LBNP) were normal and unaffected by physiological hyperinsulinemia. Therefore, because of daily life hyperinsulinemia, chronic sympathetic stimulation could be operative in these patients and may explain the increased incidence of hypertension and/or cardiovascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and may contribute to hypertension by increasing sympathetic activity, peripheral vascular resistance, renal sodium retention [107], and vascular smooth muscle tone and proliferation [108,109].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 888
“Increases in bulk muscle blood flow have been demonstrated at both physiological (108, 132, 134, 135, 137, 140, 143) and supraphysiological (123, 134, 140, 142, 150, 157) concentrations of insulin.”
BackgroundMetformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
“Insulin resistance is related to hypertension in both diabetic and non-diabetic individuals and may contribute to hypertension by increasing sympathetic activity, peripheral vascular resistance, renal sodium retention [107], and vascular smooth muscle tone and proliferation [108,109].”
BackgroundScherrer, U., & Sartori, C. (1997) · Circulation · doi:10.1161/01.cir.96.11.4104 · Cited by 371
Blood flow and muscle metabolism: a focus on insulin action
Clark, M. G., Wallis, M. G., Barrett, E. J., Keske, M. A., Richards, S. M., Clerk, L. H., & Rattigan, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00408.2002 · Cited by 359
“Yet, not all studies agree with these findings, as a number of research groups have found no impairment of insulinstimulated blood flow in type 2 diabetics (40, 172, 184).”
BackgroundResultVascular function, insulin resistance and fatty acids
Steinberg, H. O., & Baron, A. (2002) · Diabetologia · doi:10.1007/s00125-002-0800-2 · Cited by 346
“A number of studies by a variety of techniques have now confirmed the NO dependency of insulin-mediated vasodilation in other vascular beds such as the forearm [13, 38, 39], supporting the notion that this effect is probably generalised in insulin sensitive tissues.”
BackgroundImpact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension
Huggett, R. J., Scott, E. M., Gilbey, S. G., Stoker, J. B., Mackintosh, A. F., & Mary, D. A. S. G. (2003) · Circulation · doi:10.1161/01.cir.0000103123.66264.fe · Cited by 305
Insulin-induced vasodilatation: physiology or pharmacology?
Yki‐Järvinen, H., & Utriainen, T. (1998) · Diabetologia · doi:10.1007/s001250050919 · Cited by 261
Zheng, R., & Mao, Y. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0562-y · Cited by 252
Keske, M. A., Montagnani, M., & Quon, M. J. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0018-9 · Cited by 232
“In insulin-resistant people, basal limb blood flow is generally not altered [61, 62 ].”
BackgroundInsulin and Insulin-Like Growth Factor in Normal and Pathological Cardiovascular Physiology
Sowers, J. R. (1997) · Hypertension · doi:10.1161/01.hyp.29.3.691 · Cited by 184
Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Self-citationSYMPATHETIC NERVOUS SYSTEM, DIABETES, AND HYPERTENSION
Perin, P. C., Maule, S. V., & Quadri, R. (2001) · Clinical and Experimental Hypertension · doi:10.1081/ceh-100001196 · Cited by 175
Lu, Y., Chang, C. C., Chou, R., Tsai, Y., Liu, L.-K., Chen, L., Huang, P., & Lin, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01391-7 · Cited by 142
Hogikyan, R. V., Gałecki, A. T., Pitt, B., Halter, J. B., Greene, D. A., & Supiano, M. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4907 · Cited by 151
Levinger, I., Goodman, C. A., Hare, D. L., Jerums, G., & Selig, S. (2007) · Diabetes Care · doi:10.2337/dc07-0841 · Cited by 124
Scherrer, U., & Sartori, C. S. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420315 · Cited by 117
Neuroadrenergic Dysfunction Along the Diabetes Continuum
Straznicky, N. E., Grima, M. T., Sari, C. I., Eikelis, N., Lambert, É., Nestel, P. J., Esler, M., Dixon, J. B., Chopra, R., Tilbrook, A. J., et al. (2012) · Diabetes · doi:10.2337/db12-0138 · Cited by 112
“(26) found no difference in basal norepinephrine kinetics in lean T2D versus matched control subjects.”
BackgroundAre we misunderstanding beta-blockers
Cruickshank, J. M. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.01.069 · Cited by 109
Anfossi, G., Mularoni, E., Burzacca, S., Ponziani, M. C., Massucco, P., Mattiello, L., Cavalot, F. L., & Trovati, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.121 · Cited by 107
“It has also been observed that insulininduced vasodilation, which is another NO-mediated phenomenon (28,29), is preserved in lean NIDDM patients (32).”
BackgroundPang, X., Zhao, J., Zhang, W., et al. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.02.002 · Cited by 98
Activation of the Sodium-Potassium Pump Contributes to Insulin-Induced Vasodilation in Humans
Tack, C. J., Lutterman, J. A., Vervoort, G., Thien, T. A., & Smits, P. (1996) · Hypertension · doi:10.1161/01.hyp.28.3.426 · Cited by 78
Self-citationUtriainen, T., Nuutila, P., Takala, T., Vicini, P., Ruotsalainen, U., Rönnemaa, T., Tolvanen, T., Raitakari, M., Haaparanta‐Solin, M., Kirvelä, O., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119591 · Cited by 75
“also had worse glycemic control than those in the other studies (3, 17, 18).”
BackgroundResultInsulin, nitric oxide and the sympathetic nervous system
Sartori, C. S., & Scherrer, U. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917110-00003 · Cited by 67
Bredie, S. J. H., Tack, C. J., Smits, P., & Stalenhoef, A. F. H. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvb.17v07.1465 · Cited by 66
Self-citationThe PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models
Kobayashi, T., Matsumoto, T., & Kamata, K. (2005) · Journal of Smooth Muscle Research · doi:10.1540/jsmr.41.283 · Cited by 61
“Since a high plasma concentration of insulin reportedly leads to an increased firing rate in sympathetic nerves and to enhanced NE release, an increase in blood pressure may result (Gans et al., 1991; Tack et al., 1996).”
BackgroundDisparity of autonomic control in type 2 diabetes mellitus
Huggett, R. J., SCOTT, E. M., Gilbey, S. G., Bannister, J., Mackintosh, A., & Mary, D. A. S. G. (2004) · Diabetologia · doi:10.1007/s00125-004-1601-6 · Cited by 56
“Our findings and those of others, regarding the involvement of sympathetic activation in the pathogenesis of hypertension [55] and the common association between type 2 diabetes and hypertension [53], indicate that the increased sympathetic drive to the periphery is one of the mechanisms leading to an increased risk o…”
Utriainen, T., Mäkimattila, S., Virkamäki, A., Bergholm, R., & Yki‐Järvinen, H. (1996) · Diabetologia · doi:10.1007/s001250050601 · Cited by 55
“At high insulin concentrations, defects in blood flow have been found in subjects with marginally elevated blood pressure [43], and in patients with IDDM [47] and NIDDM [48], although these findings have not been uniform in either hypertensive subjects [49, 50] or in patients with NIDDM [51, 52].”
ResultInfluentialMechanisms of Impaired Endothelial Function Associated with Insulin Resistance
Miller, A. W., Hoenig, M. E., & Ujhelyi, M. R. (1998) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849800300205 · Cited by 53
“Indeed, hyperinsulinemia has been related to increased catecholamine outflow regardless of the presence of insulin resistance (12,13).”
BackgroundHeightened norepinephrine-mediated vasoconstriction in type 2 diabetes
Hogikyan, R. V., Gałecki, A. T., Halter, J. B., & Supiano, M. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90242-1 · Cited by 54
Relationships of Adrenoceptor Polymorphisms with Obesity
Masuo, K., & Lambert, G. W. (2011) · Journal of Obesity · doi:10.1155/2011/609485 · Cited by 51
Changes in blood pressure and plasma catecholamine levels during prolonged hyperinsulinemia
Kern, W., Peters, A., Jan Born, A., Fehm, H. L., & Schultes, B. (2005) · Metabolism · doi:10.1016/j.metabol.2004.10.005 · Cited by 50
“In this context, it is worth mentioning that there is evidence that in the condition of chronic hyperinsulinemia the hormone loses its vasodilatory action [32,51,52], whereas its stimulatory influence on the sympathetic nervous systems remains preserved [17-19,25].”
BackgroundResultInfluentialMaissan, P., Mooij, E., & Barberis, M. (2021) · Biology · doi:10.3390/biology10030194 · Cited by 52
Lee, D., Park, J. E., Kim, S. Y., et al. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00927-5 · Cited by 47
Chiu, T.-H., Huang, Y., Chiu, H., Wu, P.-Y., Chiou, H.-Y. C., Huang, J., & Chen, S. (2020) · Diagnostics · doi:10.3390/diagnostics10121081 · Cited by 47
“TyG index has been associated with incident hypertension in a Chinese population [36], possibly due to insulin resistance-related hyperinsulinemia and a subsequent increase in sympathetic nervous system activity [37] and renin-angiotensin-aldosterone system activation [38].”
BackgroundLembo, G., Vecchione, C., Izzo, R., Fratta, L., Fontana, D., Marino, G., Pilato, G., & Trimarco, B. (2000) · Circulation · doi:10.1161/01.cir.102.5.552 · Cited by 44
Insulin action in muscle and adipose tissue in type 2 diabetes: The significance of blood flow
Lambadiari, V., Τriantafyllou, Κ., & Dimitriadis, G. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.626 · Cited by 42
Galletti, F., Strazzullo, P., Capaldo, B., Carretta, R., Fabris, F. M., Ferrara, L. A., Glorioso, N., Semplicini, A., & Mancini, M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917030-00018 · Cited by 39
Benedict, C., Dodt, C., Hallschmid, M., Lepiorz, M., Fehm, H. L., Jan Born, A., & Kern, W. (2005) · Metabolism · doi:10.1016/j.metabol.2005.04.026 · Cited by 38
“Thus, hypertension after insulin administration can be a consequence of a sympathoexcitatory effect in the brain that causes vasoconstriction and remains unopposed by peripheral vasodilatation in insulin-resistant subjects [39-42].”
BackgroundRennings, A. J. M., Smits, P., Stewart, M. W., & Tack, C. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-01467 · Cited by 37
“Effect of rosiglitazone on the vascular actions of insulin Hyperinsulinemia ( 1,700 pmol/l) did not change FBF during either treatment, consistent with persistent vascular insulin resistance (treatment effect for rosiglitazone 8.2% [95% CI 27.2 to 8.0], P 0.318) (Fig.”
MethodInfluentialSelf-citationAsensio, C. S., Jimenez, M., Kühne, F., Rohner‐Jeanrenaud, F., & Muzzin, P. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3490 · Cited by 36
Deng, D., Chen, C., Wang, J., Luo, S., & Feng, Y. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14652 · Cited by 36
Liu, T., Xuan, H., Yin, J., et al. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s391905 · Cited by 35
Do High Proinsulin and C-Peptide Levels Play a Role in Autonomic Nervous Dysfunction?
Töyry, J. P., NISKANEN, L. K., Mäntysaari, M., Länsimies, E., Haffner, S. M., Miettinen, H., & Uusitupa, M. I. J. (1997) · Circulation · doi:10.1161/01.cir.96.4.1185 · Cited by 34
Kim, S., Park, G.-H., Yang, J. H., Chun, S. H., Yoon, H., & Park, M.-S. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.9 · Cited by 32
Effects of metformin on endothelial health and erectile dysfunction
Patel, J. P., Lee, E. H., Mena, C. I., & Walker, C. N. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.03.52 · Cited by 33
“Insulin resistance drives ED though complex mechanisms involving endothelial dysfunction, impaired vasodilatation, increased sympathetic tone, inflammation, and atherosclerosis (5-7).”
BackgroundXu, J., Xu, W., Chen, G., Hu, Q., & Jiang, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1288693 · Cited by 35
“…by insulin in the body, leading to compensatory overproduction of insulin by the body, which increases sympathetic nervous system activity and promotes the body to secrete more epinephrine and norepinephrine, ultimately increasing cardiac output and peripheral vascular resistance (30, 31).”
BackgroundHassan, N. A., El‐Bassossy, H. M., Fahmy, A., & Mahmoud, M. F. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.03.044 · Cited by 31
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Donker, A. J. M., & Stehouwer, C. D. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01554.x · Cited by 30
Liu, D., Guan, L., Zhao, Y., Liu, Y., Sun, X., Li, H., Yin, Z., Li, L., Ren, Y., Wang, B., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-0439-8 · Cited by 25
Valensi, P. E., Nguyen, T. N., Idriss, S., Cazes, P., Karam, G., Pariès, J., Miossec, P., & Attali, J. R. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90347-x · Cited by 28
Insulin stimulates epinephrine release under euglycemic conditions in humans
Tack, C. J., Lenders, J. W. M., Willemsen, J. J., van Druten, J. A. M., Thien, T., Lutterman, J. A., & Smits, P. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90251-7 · Cited by 28
Self-citationBeta-Blockers and Diabetes: The Bad Guys Come Good
Cruickshank, J. M. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1022146721098 · Cited by 26
Phillips, L. K., Peake, J. M., Zhang, X., Hickman, I. J., Kolade, O. O., Sacre, J. W., Be, H., Simpson, P., Li, S. H., Whitehead, J. P., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0413 · Cited by 25
Effects of diosmin and crocin on metabolic syndrome-associated cardio-vascular complications in rats
El‐Fawal, R., Fayoumi, H. M. E., & Mahmoud, M. F. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01700-8 · Cited by 26
Abbink, E. J., Walker, A. J., van der Sluijs, H. A., Tack, C. J., & Smits, P. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.269 · Cited by 22
“pronounced than previous studies have shown [1,3].”
BackgroundSelf-citationThounaojam, M. C., Jadeja, R. N., Ansarullah, et al. (2010) · Eisei kagaku · doi:10.1248/jhs.56.92 · Cited by 21
Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia
Paramore, D. S., Fanelli, C. G., SHAH, S. D., & Cryer, P. E. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.5.e872 · Cited by 22
“Furthermore, the present data confirm that hyperinsulinemia per se stimulates sympathetic neural activity (1, 2, 4, 5, 9, 29, 39, 47, 50, 55), here assessed with the FNESO, without stimulating adrenomedullary activity, an issue that is still debated (33).”
BackgroundKobayashi, T., Kaneda, A., & Kamata, K. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705438 · Cited by 21
“Since a high plasma concentration of insulin reportedly leads to an increased firing rate in sympathetic nerves and to enhanced noradrenaline (NA) release, this may result in an increase in blood pressure (Gans et al., 1991; Tack et al., 1996).”
BackgroundZhou, K., & Cen, J. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0858-6 · Cited by 20
RetractedLuo, S., Ezrokhi, M., Cominos, N., Tsai, T., Stoelzel, C. R., Trubitsyna, Y., & Cincotta, A. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00630-x · Cited by 18
Argoty-Pantoja, A. D., Velázquez‐Cruz, R., Meneses‐León, J., Salmerón, J., & Rivera‐Paredez, B. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01925-w · Cited by 19
Nakagomi, A., Kodani, E., Takano, H., Uchida, T., Sato, N., Ibuki, C., Kusama, Y., Seino, Y., Munakata, K., Mizuno, K., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1078 · Cited by 18
Prognostic factors for successful insulin therapy in subjects with type 2 diabetes
Wolffenbuttel, B. H. R. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(98)00145-4 · Cited by 17
The Role of Adenosine in Insulin-Induced Vasodilation
Abbink, E. J., Vervoort, G., Tack, C. J., Lutterman, J. A., Schaper, N. C., & Smits, P. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199909000-00009 · Cited by 16
Self-citationInsulin and non-insulin mediated vasodilation and glucose uptake in patients with type 2 diabetes
Scheede‐Bergdahl, C., Olsen, D. B., Reving, D., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.06.029 · Cited by 15
Vuvor, F., Steiner‐Asiedu, M., Armar‐Klemesu, M., & Armah, S. M. (2011) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-011-0035-1 · Cited by 14
Peripheral blood flow and noradrenaline responsiveness: the effect of physiological hyperinsulinemia
de Haan, C. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00035-7 · Cited by 14
Haemodynamic actions of insulin
Tack, G. J. J., Lenders, J. W. M., Goldstein, D. S., Lutterman, J. A., Smits, P., & Thien, T. A. (1998) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199801000-00016 · Cited by 14
Self-citationVasomotor Responses to Hypoxia in Type 2 Diabetes
Weisbrod, C. J., Eastwood, P. R., O’Driscoll, G., Walsh, J. H., Best, M., Halliwill, J. R., & GREEN, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2073 · Cited by 14
Muscle Sympathetic Nerve Activity in Patients with Acromegaly
Capaldo, B., Lembo, G., Rendina, V., Guida, R., Marzullo, P., Colao, A. A. L., Lombardi, G., & Saccà, L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6802 · Cited by 14
Beta-blockers in the third millennium - when are they really indicated
Prichard, B. N. C., Jm, C., & Graham, B. R. (2001) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 12
Cincotta, A. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713255 · Cited by 11
“References for Figure 5: a [94,188,367– 373]; b [186,187,293–295,349,374–379]; c [141,142,149,155,179,380,381]; d [312,313,340,382– 392], e [305,393–398], f [394,395]; g [305,399,400]; h [401–403]; i [403,404]; j [141,142,381]; k [405]; l [188,406–412]; m [94,185,188,189,297,344–346,375,413–419]; n [420– 425]; o [426,…”
Zhang, J., Wang, R., Liu, Q., Song, G., & Tang, X. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.014 · Cited by 12
Tack, C. J., Heeremans, M., Thien, T. A., Lutterman, J. A., & Smits, P. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199608000-00010 · Cited by 11
Self-citationMicrocirculatory effects of KATP channel blockade by sulphonylurea derivatives in humans
Abbink, E. J., Wollersheim, H. C. H., Netten, P. M., et al. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00964.x · Cited by 10
Self-citationForearm vasoconstrictor response in uncomplicated type 1 diabetes mellitus
van Gurp, P. J. M., Willemsen, J. J., Lenders, J. W. M., Ross, H. A., Sweep, F. C. G. J., Smits, P., & Tack, C. J. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01707.x · Cited by 10
Self-citationEffects of Insulin on the Kidney and the Cardiovascular System
Ferrannini, E., & Nannipieri, M. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4499-9_12 · Cited by 9
Frontoni, S., Pellegrinotti, M., Bracaglia, D., Farrace, S., Caselli, A., Baroni, A., Angelis, C. D., Menzinger, G., & Gambardella, S. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00349.x · Cited by 9
Hermann, T. S., Ihlemann, N., Domínguez, H., Rask‐Madsen, C., Køber, L., & Torp-Pedersen, C. T. (2004) · Endothelium · doi:10.1080/10623320490904098 · Cited by 9
Association between triglyceride glucose index and H-type hypertension in postmenopausal women
Ding, Z., Du, S., Yang, Y., Yu, T., & Hong, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1224296 · Cited by 8
The relation of leptin and insulin with obesity-related cardiovascular risk factors in US adults
Reis, J. P., Macera, C. A., Wingard, D. L., Araneta, M. R. G., Lindsay, S. P., & Marshall, S. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.015 · Cited by 8
Khoo, J., Low, S. K., Irwan, B., et al. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.09 · Cited by 8
Madden, K. M., Tedder, G., Lockhart, C., & Meneilly, G. S. (2008) · Diabetes Care · doi:10.2337/dc08-1058 · Cited by 8
“Insulin has profound cardiovascular properties, resulting in simultaneous adrenergic (4) and vasodilatory (5,6) responses that have opposing influences on blood pressure.”
BackgroundChen, Y., Wu, J., Tang, Y., Li, Z., Wen, Q., Sun, X., Hong, Y., Lu, Y. W., & Cai, J. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.08.022 · Cited by 8
Insulin Resistance and Cardiovascular Disease
Haley, J., & Urbina, E. M. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-25057-7_12 · Cited by 7
Li, M., Zhang, H.-P., Cheng, Y., Sun, L., Chen, S., Duan, X., Xian, C., Wu, S., & Yin, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05112-w · Cited by 5
“This activation establishes a feedback loop of neural and humoral overactivity, culminating in a rise in cardiac output and increased peripheral vascular resistance [49, 50].”
Wang, L., Cao, T., Li, J., Ding, C., Li, J., Ying, H.-B., Liu, L., & Huang, X. B. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.10.006 · Cited by 5
Vascular Effects of Metabolic Inhibition by 2-Deoxy-D-Glucose in Humans
Abbink, E. J., Tack, C. J., & Smits, P. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200101000-00011 · Cited by 5
Self-citationBao, K., Bao, D., Huang, Z., Gu, W., & Chen, K. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004118 · Cited by 4
de Almeida, A. P., Juvanhol, L. L., Bersch-Ferreira, Â. C., Torreglosa, C. R., Marcadenti, A., Weber, B., Bressan, J., & Hermsdorff, H. H. M. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521005018 · Cited by 4
“It is known that IR favours the increase in peripheral vascular resistance through increased activity of the sympathetic nervous system(70).”
BackgroundAcupuncture Therapy for Hypertension and Hypotension
Kang, X., & Xia, Y. (2010) · Springer eBooks · doi:10.1007/978-3-642-10857-0_11 · Cited by 4
Zhang, Y., Gesang, P., Zhou, Y., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-21160-x · Cited by 3
Olsen, H., Groop, L., & Länne, T. (2003) · European Journal of Applied Physiology · doi:10.1007/s00421-003-0894-3 · Cited by 3
“During HI, LBNP resulted in similar changes in HR, BP and FVR as compared with control LBNP (Tack et al. 1996b; Fig.”
BackgroundResultInfluentialLee, D., Park, J. E., Kim, S. Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-601926/v1 · Cited by 3
Ishida, S., Shinohara, Y., Sakaguchi, T., Katsuki, S., Kawano, K., Ueno, T., Maki, K., Nohara, C., Fujii, T., Abe, M., et al. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004087 · Cited by 2
Insulin and Insulin-Like Growth Factor I (IGF-I) Effects on Ca2+ and Nitric Oxide in Diabetes
Sowers, J. R. (1998) · Endocrine updates · doi:10.1007/978-1-4615-5569-8_8 · Cited by 2
Cumulative triglyceride-glucose index and hypertension risk: a longitudinal cohort study
Wu, Z., Wu, D., Xu, S., Borné, Y., Lan, Y., & Chen, S. (2025) · BMC Public Health · doi:10.1186/s12889-025-25261-z · Cited by 1
Cardenas-Juarez, A., García-Hernández, M. H., Lira-Hernández, F. I., Lara-Ramirez, E. E., Rivas-Santiago, B., Vargas-Morales, J. M., & Portales‐Pérez, D. P. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251405802 · Cited by 1
“56,57 Nevertheless, this study has several limitations that should be acknowledged.”
Effects of Insulin on the Vascular System
Steinbergr, H. O. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:001 · Cited by 1
“Other groups have reported that blood pressure in response to euglycemic hyperinsulinemia increased (29), decreased (95), or remained unchanged ( 96 ) in obese and diabetic subjects.”
BackgroundHuvers, F. C. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00319-2 · Cited by 1
Metadata
- Authors
- Tack, C. J. J., Smits, P., Willemsen, J. J., Lenders, J. W. M., Thien, T., & Lutterman, J. A.
- Affiliations
- Department of Internal Medicine, Division of General Internal Medicine, University Hospital Nymegen Nymegen, The Netherlands
- Department of Experimental and Chemical Endocrinology, University Hospital Nymegen Nymegen, The Netherlands
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1996-01-01
- Volume
- 45
- Issue
- 1
- Pages
- 15-22
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2165801681
- Cited by
- 117
- References
- 0
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 1 · 2023: 10 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 2 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 2
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Diabetes Fonds
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, insulin resistance, hyperinsulinemia, sympathetic nervous system, vascular tone, norepinephrine spillover, forearm blood flow, lower body negative pressure, postprandial insulin response, cardiovascular risk, norepinephrine kinetics, glucose infusion
- MeSH terms
- Adult, Blood Flow Velocity, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Eating, Female, Humans, Hyperinsulinism, Infusions, Intravenous, Insulin, Male, Middle Aged, Muscle, Smooth, Vascular, Norepinephrine, Sympathetic Nervous System, Vasodilation, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
